06628.HK
Transcenta Holding Limited
HKSE · Healthcare · Biotechnology · CN
HKD 0.74
+9.70%Year over year
Reported trailing growth
- Revenue
- +201.0%
- EBITDA
- +52.5%
- EBIT
- +42.3%
- EPS
- +40.9%
- Free cash flow
- +58.5%
- Operating cash flow
- +59.2%
Forward estimates
Based on analyst estimates
- Revenue
- +545.2%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -58.6%
- EBITDA
- +35.6%
- EBIT
- +30.3%
- Net income
- +31.6%
- EPS
- +33.3%
- Free cash flow
- +33.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026